Regulatory: AstraZeneca, Praecis
Monday, 15 March, 2004
AstraZeneca has received final European marketing approval for its new breast cancer drug Faslodex, following a recommendation from a European Union expert committee in November.
Faslodex is indicated for the treatment of advanced breast cancer in post-menopausal women whose cancer has progressed on previous anti-oestrogen treatments such as tamoxifen.
AstraZeneca, Europe's second biggest drugmaker, said it was the first new type of treatment for hormone receptor positive advanced breast cancer to be approved in the European Union since 1995. It expects first launches of Faslodex in Europe in the second quarter of 2004.
The drug has been on sale since May 2002 in the United States, where sales reached US$77 million in 2003.
Praecis
The US Food and Drug Administration called a halt to a Phase I clinical trial of Massachusetts-based Praecis Pharmaceuticals' PPI-2458 drug in non-Hodgkin's lymphoma until certain questions have been answered.
"We remain committed to the development of PPI-2458 for non-Hodgkin's lymphoma, as well as additional evaluation of its activity in other cancers," said Praecis' chief medical officer, Marc Garnick.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
